Skip to main content
PMC home page
Frontiers in Neuroscience logoLink to Frontiers in Neuroscience
. 2020 Jun 23;14:636. doi: 10.3389/fnins.2020.00636

Disrupted Sleep and Circadian Rhythms in Schizophrenia and Their Interaction With Dopamine Signaling

Anna Ashton 1, Aarti Jagannath 1,*
PMCID: PMC7324687  PMID: 32655359

Abstract

Sleep and circadian rhythm disruption (SCRD) is a common feature of schizophrenia, and is associated with symptom severity and patient quality of life. It is commonly manifested as disturbances to the sleep/wake cycle, with sleep abnormalities occurring in up to 80% of patients, making it one of the most common symptoms of this disorder. Severe circadian misalignment has also been reported, including non-24 h periods and phase advances and delays. In parallel, there are alterations to physiological circadian parameters such as body temperature and rhythmic hormone production. At the molecular level, alterations in the rhythmic expression of core clock genes indicate a dysfunctional circadian clock. Furthermore, genetic association studies have demonstrated that mutations in several clock genes are associated with a higher risk of schizophrenia. Collectively, the evidence strongly suggests that sleep and circadian disruption is not only a symptom of schizophrenia but also plays an important causal role in this disorder. The alterations in dopamine signaling that occur in schizophrenia are likely to be central to this role. Dopamine is well-documented to be involved in the regulation of the sleep/wake cycle, in which it acts to promote wakefulness, such that elevated dopamine levels can disturb sleep. There is also evidence for the influence of dopamine on the circadian clock, such as through entrainment of the master clock in the suprachiasmatic nuclei (SCN), and dopamine signaling itself is under circadian control. Therefore dopamine is closely linked with sleep and the circadian system; it appears that they have a complex, bidirectional relationship in the pathogenesis of schizophrenia, such that disturbances to one exacerbate abnormalities in the other. This review will provide an overview of the evidence for a role of SCRD in schizophrenia, and examine the interplay of this with altered dopamine signaling. We will assess the evidence to suggest common underlying mechanisms in the regulation of sleep/circadian rhythms and the pathophysiology of schizophrenia. Improvements in sleep are associated with improvements in symptoms, along with quality of life measures such as cognitive ability and employability. Therefore the circadian system holds valuable potential as a new therapeutic target for this disorder.

Keywords: circadian, sleep, schizophrenia, dopamine, clock, SCRD

Introduction

Schizophrenia is a severe psychiatric disorder, it is a leading cause of disability affecting nearly 1% of the global population (Vos et al., 2017; Moreno-Küstner et al., 2018). It is heterogeneous in nature, characterized by a combination of positive symptoms, including hallucinations and disorganized speech, negative symptoms such as social withdrawal, and cognitive symptoms. The neural mechanisms underlying it are unclear, but the most widely accepted hypothesis is aberrant dopamine (DA) signaling. Sleep and circadian rhythm disruption (SCRD) is a common feature of the disorder and is closely associated with symptom severity and patient quality of life (Cosgrave et al., 2018a). It is now considered to be more than symptomatic and is thought to contribute to the pathophysiology of schizophrenia (Manoach et al., 2016; Cosgrave et al., 2018b).

Circadian rhythms are oscillations in physiology and behavior of around 24 h, having evolved across phylogeny to enable an organism to anticipate daily changes in the external environment, such as the light/dark cycle. The endogenous circadian clock drives these rhythms. In mammals, this consists of a molecular transcriptional-translational feedback loop (TTFL) in which the transcription factors CLOCK and BMAL1 induce expression of the clock genes Per1/2 and Cry1/2, which then feedback to repress CLOCK and BMAL1 transcriptional activity (Figure 1A; Reppert and Weaver, 2002). This core clock machinery is present in almost every cell throughout the body (Dibner et al., 2010). Peripheral clocks are aligned by the master circadian pacemaker in the suprachiasmatic nuclei (SCN) of the hypothalamus, resulting in a coordinated network of cell autonomous circadian oscillators driving rhythmic outputs (Figure 1B). The SCN receives light input directly from the retina, which acts as the primary time cue, or “zeitgeber,” for entrainment of the clock to changes in the external environment. The sleep/wake cycle is one such rhythm under the control of the circadian clock, but it is also driven by homeostatic sleep pressure, which accumulates during wakefulness and dissipates with sleep (Borbely and Achermann, 1999). Numerous neurotransmitters are involved in the regulation of sleep, including DA, which is an established regulator of the sleep/wake cycle, exerting a potent wake-promoting activity (Eban-Rothschild et al., 2018). There is also evidence that DA has roles in the regulation of circadian rhythms, such as through modulation of SCN entrainment and behavioral oscillators.

FIGURE 1.

FIGURE 1

Open in a new tab

The circadian clock. The clock consists of a molecular transcriptional-translational feedback loop whereby the transcription factors, CLOCK and BMAL1, heterodimerize and induce expression of the core clock genes, Per and Cry (A). PER and CRY then feedback onto CLOCK and BMAL1 by inhibiting their transcriptional activity. This feedback loop cycles with a period of around 24 h and is present in cells throughout the body, thus driving both the central circadian clock and peripheral clocks. Collectively these drive daily rhythms in physiology and behavior, such as changes in alertness levels, secretion of the stress hormone cortisol and core body temperature (B). Adapted from Jagannath et al. (2013), used with permission.

The mechanisms underlying SCRD in schizophrenia are currently unclear. However the involvement of DA in both schizophrenia pathogenesis and the sleep and circadian systems suggests that it may be involved. Here, we examine the interplay of SCRD with DA in schizophrenia, assessing the role of DA in the regulation of sleep and circadian rhythms, as well as the circadian influence on DA itself.

Sleep and Circadian Rhythm Disruption in Schizophrenia

Sleep and circadian rhythm disruption is widespread and well documented in schizophrenia. Indeed sleep disruption has been noted to be associated with mental health problems for over a century and the prevalence of SCRD in schizophrenia was reported to be as high as 80% (Wirz-Justice et al., 2001; Chouinard et al., 2004; Afonso et al., 2011; Bromundt et al., 2011). These showed that patients with schizophrenia had disrupted sleep/wake cycles as measured by wrist actigraphy and melatonin and cortisol profiles, which are markers of endogenous rhythmicity in patients with schizophrenia. However, as most of these studies lacked suitable control subjects, it was difficult to draw conclusions about confounding effects from medication and socio-economic factors including employment status. Wulff et al. (2012), were amongst the first to systematically evaluate circadian disruption in a cohort with schizophrenia against healthy unemployed controls and showed all of the 20 patients assessed had significant SCRD, but none of the controls. Importantly, the patients showed wide heterogeneity in phenotypes, including advanced/delayed phase, non-24 h rhythms that were not entrained by the light/dark cycle and fragmented and irregular sleep patterns, perhaps reflecting the heterogeneity in the disease itself. The nature and extent of SCRD in schizophrenia have been covered in previous reviews and we point the reader to these for further information (Wulff et al., 2010; Jagannath et al., 2013; Chan et al., 2017; Cosgrave et al., 2018b).

Causal Role of Sleep and Circadian Rhythm Disruption

Recent studies provide evidence that sleep disruption may indeed play a causal role in the development of psychosis. It is clear that SCRD can precede the appearance of psychosis on the one hand, and exacerbate negative outcomes on the other. Fragmented sleep and blunted circadian rhythmicity of behavior have been observed in adolescents and young adults at risk for psychosis (Castro et al., 2015) and SCRD predicted the severity of psychosis symptoms and psychosocial impairment at 1 year follow-up in adolescents with clinically high risk for psychosis (Lunsford-Avery et al., 2017). With similar findings in bipolar disorder (Ng et al., 2015), now often considered to be on the same spectrum as schizophrenia, further long-term studies are required to assess the predictive power of SCRD in early diagnosis. Even in healthy subjects, psychotic episodes can be predicted by poor perceived sleep quality in combination with reduced sleep duration (Cosgrave et al., 2018b). Further, sleep deprivation, or restricted sleep to mimic insomnia in healthy subjects leads to symptoms associated with schizophrenia such as reduced prepulse inhibition, increased delusions and hallucinations, and psychotic episodes (Petrovsky et al., 2014; Reeve et al., 2018).

Disrupted sleep in schizophrenia is associated with poor quality of life, higher rates of relapse and suicide (Hofstetter et al., 2005; Pompili et al., 2009; Palmese et al., 2011), and the stabilization of sleep can have beneficial effects. A controlled trial administering cognitive behavioral therapy (CBT) to reduce insomnia in a cohort of over 3000 university students had the concomitant outcome of reducing the appearance of paranoid delusions and hallucinations in those subjects whose insomnia was reduced (Freeman et al., 2017). This approach has also been used in patients with schizophrenia where improvements in sleep are associated with reduced persecutory delusions and hallucinations (Myers et al., 2011; Waite et al., 2016). Pharmacotherapy for sleep stabilization includes traditional sedative-hypnotics such as benzodiazepines, and second generation sedating antipsychotics such as quetiapine, olanzapine and risperidone improve sleep quality, and pharmacotherapy for sleep also correlates with an improvement in negative symptoms (Kajimura et al., 1995; Yamashita et al., 2004; Kluge et al., 2014). Pharmacotherapy is administered with caution however, as many sedative-hypnotics impair slow-wave sleep and REM sleep patterns, sleep parameters which may already be impaired in schizophrenia.

Clinical studies examining melatonin use as an add-on therapy in schizophrenia suggest that it may also be effective at ameliorating sleep disruption in this disorder (reviewed in Bastos et al., 2019). Melatonin is a key hormonal output of the central clock, its rhythmic release acts to signal circadian time to the brain and peripheral tissues. Administered alongside antipsychotic medication, it results in improved sleep measures including sleep efficiency and duration (Shamir et al., 2000; Kumar et al., 2007). Furthermore, animal studies have demonstrated that it reduces schizophrenia-like behaviors in mice, suggesting that it may also be effective at treating symptoms such as cognitive impairment and social withdrawal (da Silva Araújo et al., 2017; Onaolapo et al., 2017). However, studies which have looked at the effect of melatonin on the psychotic symptoms in patients, although limited, show conflicting results. A reduction in symptom severity has been reported with add-on treatment of both melatonin (Modabbernia et al., 2014) and the melatonin receptor agonist, ramelteon (Mishra et al., 2020). In contrast, Romo-Nava et al. (2014) did not detect any improvement resulting from melatonin administration over placebo, although this study also included patients with bipolar disorder. Inconsistencies in melatonin efficacy may be due to deficiencies in its target regions or its receptors. Indeed, a polymorphism in the MT1 melatonin receptor gene is associated with schizophrenia (Park et al., 2011), indicating that the receptor expression may be altered in some patients.

Together the evidence from these studies suggests SCRD could indeed play a causal role in the development of schizophrenia and that the stabilization of SCRD has beneficial outcomes. As an extension, these findings suggest the SCRD could be a manifestation of a dysfunctional circadian system, which could underlie aspects of the pathophysiology of schizophrenia.

Genome-wide association studies have associated mutations in circadian clock genes with an increased risk of schizophrenia; single nucleotide polymorphisms (SNPs) in CLOCK, PER2, PER3, RORB, and TIMELESS have been associated with the disorder as assessed within relatively small groups of patients, numbering a few hundred (Takao et al., 2007; Mansour et al., 2009; Zhang et al., 2011). Whilst these associations with clock genes have not been replicated in larger studies and meta-analyses (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Pardiñas et al., 2018; Rees et al., 2019; Wang et al., 2019), these larger studies have implicated SNPs in genes with a role in dopaminergic/glutamatergic neurotransmission, mitochondrial function and immunity. All of these pathways also directly feed into the regulation of circadian rhythms or are regulated by the clock; highlighting multiple points of convergence with circadian rhythms in the pathophysiology of schizophrenia. For example, dopaminergic regulation of the clock is described in detail below and there is a growing body of literature on elevated neuroinflammation in the prefrontal cortex in schizophrenia. This has now been linked to increased nuclear factor-κB (NF-κB) transcriptional activation (Volk et al., 2019), and NF-κB function is regulated by CLOCK, with Clock deficient mice showing significantly reduced NF-κB activation in response to immunostimuli (Spengler et al., 2012).

Circadian disruption could result from aberrant synaptic networks and connectivity within the brain, which characterize both schizophrenia and bipolar disorder (Chai et al., 2011), or from a deficit at the level of clock gene expression. There is evidence for both. Blind-drunk (Bdr) is a mouse model of synaptosomal-associated protein (Snap)-25 exocytotic disruption that displays schizophrenic endophenotypes. Their circadian rhythms are fragmented and phase advanced, and there is some evidence that this arises from disruption of synaptic connectivity within the SCN, thus disrupting rhythmic outputs (Oliver et al., 2012). On the other hand, skin fibroblasts isolated from patients with chronic schizophrenia lose rhythms in the expression of the clock genes CRY1 and PER2 when compared with healthy controls (Johansson et al., 2016), and PER1/2/3 and NPAS2 mRNA levels were reported to be altered in white blood cells from schizophrenia patients (Sun et al., 2016). These studies show a deficit at the level of the molecular clock in schizophrenia that is cell autonomous, much like the clock itself. This has been replicated recently by a study analyzing gene expression in the human dorsolateral prefrontal cortex in schizophrenia and control subjects (Seney et al., 2019). By factoring time-of-death into transcriptome analysis, Seney et al. (2019) showed diurnal rhythms in gene expression of very different sets of genes in two groups, with circadian signaling showing strong rhythmic patterns in the control participants but not the schizophrenia patients. In contrast, mitochondrial signaling genes were rhythmic in the patients, but not the controls. The implications of these findings are as yet unclear, but point toward a mechanistic role for circadian rhythm, and consequently circadian disruption in schizophrenia.

Mechanisms Underlying Sleep and Circadian Disruption in Schizophrenia: Role of Dopamine?

The mechanisms underlying SCRD in schizophrenia are currently unclear. However, there is evidence from numerous studies that DA plays a role in the regulation of both sleep and the circadian system. Given that aberrant DA signaling is the longest standing hypothesis for schizophrenia pathogenesis, this may underlie the SCRD in the disorder.

Dopamine in Wake and Sleep

Dopamine is one of the major regulators of sleep and wakefulness. Evidence from numerous studies spanning mammalian species and non-mammalian models, demonstrates the importance of DA in sleep control across phylogeny (Eban-Rothschild et al., 2018). The dopaminergic neurons in the ventral tegmental area (VTA) and dorsal raphe nucleus (DRN) are key components of the neuronal circuitry for the regulation of sleep and wake states in mammals, owing to their potent wake-promoting activity (Lu et al., 2006; Eban-Rothschild et al., 2016, 2018; Cho et al., 2017; Oishi et al., 2017; Yang et al., 2018). Selective optogenetic stimulation of VTA DA neurons in mice can induce behavioral arousal responses during anesthesia (Taylor et al., 2016), and induce wakefulness during NREM sleep, even following sleep deprivation when homeostatic sleep pressure would be high (Eban-Rothschild et al., 2016). Similarly, activation of DA neurons in the DRN induces wakefulness during NREM and REM sleep, while their chemogenetic inhibition reduces wakefulness and increases NREM sleep duration (Cho et al., 2017).

Dopamine neurons in both these regions, the VTA and DRN, exhibit differential firing patterns between sleep/wake states, although there are differences in the activity patterns between the two regions. In the DRN, DA populations are primarily wake-active, and interestingly the net increase in their activity at wake onset positively correlates with the duration of the subsequent wake episode (Cho et al., 2017), as it does in the striatum (Dong et al., 2019). Therefore DA levels at wake onset may determine the length of the following wake period, and subsequently influence sleep/wake cycles. While in the VTA, there is also higher DA activity during wake, with an increase in population burst firing compared to NREM sleep, however the activity of these neurons is further increased during REM sleep compared to wake (Dahan et al., 2007; Eban-Rothschild et al., 2016), suggesting distinct roles of these two DA regions in arousal. The increase in firing of VTA neurons is accompanied by an increase in extracellular DA levels in their projection target regions, the nucleus accumbens and prefrontal cortex (Léna et al., 2005), leading to sleep/wake-state dependent changes in DA levels.

However, not all DA populations are arousal-inducing, there is also evidence for a sleep-promoting role. Selective lesions of DA neurons in the substantia nigra, which project to the dorsal striatum, leads to increased wakefulness, reduced NREM and REM sleep, and fragmentation of sleep/wake states in rats, while optogenetic stimulation of these neuron terminals leads to increased NREM sleep (Qiu et al., 2016). Furthermore, low doses of D2 receptor (D2R) agonists have been reported to induce sedative effects and increase sleep in humans and rodents (Monti et al., 1989; Hamidovic et al., 2008; Laloux et al., 2008). Although this may be due to activation of pre-synaptic autoreceptors and the subsequent inhibition of DA neurons in arousal-promoting regions (Monti and Monti, 2007).

Further evidence for the role of DA in arousal is provided by the effects of stimulants (Boutrel and Koob, 2004). Genetic and pharmacological studies have demonstrated that the primary mechanism underlying the wake-inducing action of the stimulant modafinil is an increase in DA (Wisor et al., 2001; Qu et al., 2008). This is the preferred treatment for hyper-somnias such as narcolepsy, and is thought to act through inhibition of DA reuptake. Similarly, selective DA reuptake inhibitors have also been shown to promote wakefulness in rodents and dogs (Nishino et al., 1998; Luca et al., 2018).

Collectively these studies have demonstrated that DA signaling has a key role in the regulation of sleep/wake states. Generally it serves a wake-promoting role, however its effects are bidirectional and can promote both wakefulness or sleep depending on the brain region and receptor subtypes involved. Its role in sleep/wake control is therefore complex, and the precise molecular and neuroanatomical mechanisms through which it acts are still unclear, yet it is evident that normal DA signaling is important for stable sleep/wake cycles.

Dopamine and the Circadian Clock

The sleep/wake cycle is also under circadian control to ensure that its timing is aligned with the external light/dark cycle, and the two systems are closely linked. There is growing evidence that DA is also an important modulator of the circadian system.

Dopamine signaling is involved in the functioning of two key components of the circadian system: the retina and the SCN. In the retina, it is necessary for functions including light adaptation and visual acuity (Jackson et al., 2012). Importantly, it is also one of the main modulators of retinal circadian activity (Green and Besharse, 2004) and can influence the core circadian clock, controlling the amplitude of rhythmic clock gene expression (Yujnovsky et al., 2006). There is also evidence that DA via D2R drives rhythmic expression of the photopigment melanopsin in intrinsically photosensitive retinal ganglion cells (ipRGCs; Sakamoto et al., 2005), which are the primary photoreceptors responsible for light input to the SCN (Peirson and Foster, 2006). Therefore retinal DA is a key modulator of non-visual light detection, and may be important for photic entrainment of the master clock. Indeed, Doi et al. (2006) demonstrated that genetic deletion of D2R in mice leads to a deficient masking response to light, whereby light suppresses locomotor activity during the dark period when the mice are usually active. However, the D2R null mice did exhibit normal entrainment to a light/dark cycle, and photic responses in the SCN and pineal gland were intact. These data suggest that D2R is required for behavioral responses to light, but not for other non-visual photic responses such as photic entrainment of the SCN. Although in this study D2R was deleted throughout the brain, so while retinal DA signaling may be involved, the involvement of DA signaling in other regions cannot be ruled out.

In the SCN itself, there is a high number of dopaminergic neurons, with Drd1-expressing neurons comprising approximately 60% of cells in rodents (Smyllie et al., 2016). Early studies demonstrated that DA is required for entrainment of the developing SCN, acting to synchronize fetal-maternal circadian rhythms (Mendoza and Challet, 2014). More recently, studies have suggested that DA modulation of the central clock persists into adulthood (Jones et al., 2015; Landgraf et al., 2016; Smyllie et al., 2016; Grippo et al., 2017). Studies report that Drd1-expressing SCN neurons are able to entrain and set the period of circadian rhythms in mice (Jones et al., 2015; Smyllie et al., 2016). However, this does not provide direct evidence for a role of DA itself, as the Drd1-positive cells overlap with the majority of arginine vasopressin (AVP) and vasoactive intestinal peptide (VIP) neurons, other key SCN subpopulations involved in entrainment.

However, Grippo et al. (2017) did demonstrate DA modulation of the adult SCN clock via D1R signaling. They showed that DA signaling in the mouse SCN is required for normal re-entrainment following a jet lag-like phase shift in the light/dark cycle (Grippo et al., 2017). Retrograde tracing suggested that this was mediated by direct DA innervation from the VTA, with enhancement of this DA input leading to accelerated re-entrainment. Interestingly, this facilitation of resynchronization by DA required light input, in line with previous studies that showed that administration of D1R agonist alone during constant conditions does not elicit any phase shifts in hamster (Duffield et al., 1998; Grosse and Davis, 1999). This suggests that direct midbrain DA innervation of the SCN can modulate the light-responsiveness of the master clock, enabling quicker re-entrainment. Importantly, this study also demonstrates that the level of DA tone can have a direct impact on the central clock, and therefore provides a mechanism whereby aberrant DA signaling, such as an inappropriately timed elevation in DA tone, could influence the master clock. However, this study did not detect changes in several circadian parameters following modulation of SCN DA signaling, such as the period length during constant conditions and the phase angle of entrainment. Therefore, it appears that while DA via D1R has a modulatory role of the light-responsiveness of the clock, it is not necessary for its normal functioning. Studies looking at additional measures of the circadian clock other than locomotor activity are required to elucidate the involvement of DA in the clock, given the essential role of DA in motor function (Ryczko and Dubuc, 2017).

There is also evidence for a role of DA in clock regulation outside of the SCN. As previously discussed here, DA is a major modulator of the retinal clock, in addition to this it also acts on the striatal clock. The dorsal striatum is heavily innervated by dopaminergic projections from the substantia nigra. Evidence from in vivo pharmacological and lesioning studies suggest that DA signaling via D2R is required for an intact rhythm in Per2 expression in the dorsal striatum (Hood et al., 2010). Extracellular DA levels were found to oscillate here over 24 h with a peak during night, preceding the peak in Per2 expression. However, this was measured in rats maintained under a light/dark cycle, so it is unclear whether this is an endogenous circadian rhythm that persists under constant darkness or whether it requires light input.

There is also evidence that DA can regulate circadian rhythms in hormone production and behavior. It is thought to be necessary for the rhythmic release of prolactin in the arcuate nucleus of the hypothalamus (Bertram et al., 2010), and exerts an inhibitory modulation of melatonin synthesis in the pineal gland (González et al., 2012). Melatonin is an important output of the SCN for the regulation of circadian and seasonal rhythms throughout the body, and also feeds back to the SCN itself to modulate the central clock. DA is also thought to control rhythms in activity; lesioning of dopaminergic regions leads to a lengthening in the period of wheel-running and drinking activity during constant conditions (Isobe and Nishino, 2001; Tanaka et al., 2012). However, as DA itself is under circadian control (Chung et al., 2014) as discussed below, it may be that in these cases DA is an intermediate signal between the circadian clock and clock-controlled processes, rather driving the circadian rhythms itself. Nevertheless, it appears to be an important component in the regulation of circadian-controlled processes.

However, DA is in fact able to act independently of the master clock to regulate rhythms in behavior through DA-driven pacemakers which are entrainable by two non-photic stimuli: food and methamphetamine. The DA-enhancing psychostimulant, methamphetamine, can induce circadian rhythmicity in locomotor activity in the absence of an SCN, via the methamphetamine-sensitive circadian oscillator (MASCO; Tataroglu et al., 2006). This finding led to the identification of a ‘dopamine ultradian oscillator’ (DUO), whereby ultradian oscillations in DA drive an ultradian rhythm in locomotor activity, which persists in Bmal1 null mice and is therefore independent of the circadian clock (Blum et al., 2014). Interestingly, this study used Slc6a3-/- mice to model a hyper-dopaminergic phenotype, due to their deletion of DA transporter (DAT) for DA re-uptake, a potential model for schizophrenia. Elevated DA in these mice led to aberrant ultradian activity rhythms with fragmented daily activity, which mirrors the disruptions to the rest/activity cycle observed in patients with schizophrenia (Wulff et al., 2012), suggesting a causal role for DA in these symptoms. This highlights the central role that DA has in the regulation of activity rhythms, and importantly, demonstrates a potential mechanism through which aberrant DA can lead to abnormalities in rest/activity rhythms seen in schizophrenia.

Dopamine is also necessary for the activity of the food entrainable oscillator (FEO). In the absence of an SCN this drives food anticipatory activity (FAA), whereby an increase in locomotor activity precedes mealtimes by 1 to 3 h (Liu et al., 2012; Gallardo et al., 2014). DA signaling via D1R in the dorsal striatum mediates this rhythmic activity, suggesting that DA is required for daily rhythms in feeding activity. While the underlying mechanisms are still being elucidated, these SCN-independent oscillators likely feed into the SCN to regulate rhythmic behavior in concert with the central circadian clock.

Interaction of Dopamine With Other Neurotransmitter Systems

There is evidence that DA interacts directly with other neurotransmitter systems that are involved in the regulation of sleep and the circadian clock, namely adenosine and glutamate via NMDA receptors. There is an antagonistic interaction between DA and the G-protein-coupled adenosine receptors via both D1R and D2R. The D1R heteromerize with the A1R, resulting in an inhibitory action of adenosine to dampen DA receptor response (Ciruela et al., 2011). Whereas D2R form a complex with the A2A subtype of adenosine receptors, resulting in a reciprocal antagonistic interaction whereby D2R activation can also dampen the A2AR response (Figure 2A). Activation of D2R is thought to inhibit A2AR activation of the cAMP-PKA pathway, therefore leading to inhibition of adenosine-induced protein phosphorylation and gene expression, such as of immediate-early genes (IEGs; Ferré et al., 1997; Svenningsson et al., 2000). Adenosine is involved in sleep/wake control; the accumulation of extracellular adenosine during wake and its dissipation in sleep is thought to underlie homeostatic sleep drive, or “sleep pressure” (Landolt, 2008). Furthermore, the stimulant caffeine acts primarily through antagonism of A2AR (Huang et al., 2005). Therefore, DA-mediated modulation of adenosine signaling through receptor heteromerization is a potential mechanism through which DA can modulate sleep and wakefulness, although the role of this interaction in sleep control is yet to be elucidated.

FIGURE 2.

FIGURE 2

Open in a new tab

Schematic of dopamine interaction with adenosine and NMDA signaling. (A) Dopamine (DA) D2 receptors (D2R) heteromerize with adenosine 2A receptors (A2AR) to inhibit their downstream signaling via the cAMP-PKA pathway, impacting gene expression such as immediate early genes. (B) Example of DA-mediated enhancement of NMDA receptor (NMDA-R) signaling. Activation of the dopamine D1 receptor (D1R) activates the cAMP-PKA pathway which leads to phosphorylation of the NR2B subunit of the NMDA receptor, which is thought to enhance NMDA-dependent calcium influx and therefore downstream responses such as ERK phosphorylation and subsequent transcriptional activation. On the other hand, heteromerization of D1R or D2R with NMDA receptors inhibits NMDA-mediated currents (C).

It is well-established that DA modulates NMDA receptor signaling; the two receptors can form functional heteromers and their downstream signaling pathways also interact at multiple levels (Perreault et al., 2014; Klein et al., 2019). Their interaction is complex; DA can have both a potentiating and inhibitory effect on the NMDA receptor response. Activation of D1R can enhance NMDA-mediated responses (Cepeda et al., 1993, 1998; Levine et al., 1996). Evidence suggests this is through D1R-dependent phosphorylation of the NR2B subunit of the NMDA receptor, which is thought to enhance NMDA-dependent calcium influx and therefore downstream responses such as ERK signaling (Figure 2B; Pascoli et al., 2011; Murphy et al., 2014). On the other hand, heteromerization of both the D1R and D2R with NMDA receptors leads to inhibition of NMDA currents (Figure 2C; Perreault et al., 2014). NMDA receptor activation is one of the primary mediators of light input into the SCN and therefore a key mechanism for photic entrainment of clock gene expression in the master clock (Golombek and Rosenstein, 2010). Together, these represent intriguing pathways for future investigation through which aberrant DA signaling may impact neurotransmitter systems that are central to the regulation of the sleep and circadian system.

Effects of Antipsychotic Medication on Sleep and Circadian Rhythms

Given the influence of DA on sleep and the circadian clock, it would be expected that antipsychotic drugs which act to antagonize DA receptors will also influence these systems. Generally both typical and atypical antipsychotics can improve sleep, although their effects on sleep architecture in patients are not yet fully understood. Studies using both subjective measures and polysomnographic assessments have reported an increase in total sleep time and sleep efficiency, in parallel with clinical improvements (reviewed in detail in Cohrs, 2008). However there are variable effects of different medications on specific sleep parameters, such as the percentage of REM sleep. This is likely due to their different pharmacological profiles; they each act on multiple neurotransmitter systems in addition to dopamine, including serotonin, noradrenaline, and histamine (Miyamoto et al., 2005). Rodent studies have shown that antipsychotic drugs with different receptor selectivity have differential effects on sleep/wake states (Ongini et al., 1993; Gould et al., 2016). Atypical antipsychotics generally have higher affinity for serotonin receptors, which may underlie their overall higher efficacy at improving sleep over typical antipsychotics (Cohrs, 2008). Studies on the effects of antipsychotic medication in healthy subjects have also demonstrated sleep-promoting effects, indicating that this activity is independent of schizophrenia pathology. However, in a study of subjective sleep quality in hospitalized patients, sleep disturbances were found to persist in the majority of patients undergoing antipsychotic treatment (Waters et al., 2012), demonstrating limited efficacy of antipsychotics at improving sleep in all cases. Although most of the patients in this study were on additional medication such as antidepressants or anticonvulsants, leading to potential confounds.

In addition to influencing sleep, there is also some evidence that antipsychotics affect the circadian system, with differential effects of the typical and atypical classes. The atypical antipsychotic clozapine appears to improve abnormalities in rest/activity rhythms in schizophrenia patients, in comparison to typical antipsychotics such as haloperidol (Wirz-Justice et al., 1997, 2001). These studies lacked pre-treatment baseline data however, therefore it is unclear whether haloperidol itself had a role in driving the arrhythmic rest/activity patterns in these cases. Indeed, there is evidence from studies in healthy mice to suggest that haloperidol can influence the circadian clock. Acute administration of haloperidol can induce Per1 expression in the mouse SCN via NMDA receptors and CREB signaling (Viyoch et al., 2005). Whereas chronic treatment can suppress Per1 expression across various brain regions (Coogan et al., 2011), but has no effect on Bmal1 in most of these regions, suggesting that alterations in the negative arm of the core clock TTFL did not impact on the positive arm here. On the other hand, clozapine was not found to influence clock genes in a small sample study analyzing their expression in white blood cells from patients following an 8 week treatment course (Sun et al., 2016). There were no improvements in the abnormal rhythmic clock gene expression, despite the improvements in circadian rhythms in response to clozapine treatment previously reported. Overall, the actions of antipsychotic medication on the circadian system are unclear from these limited studies. Nevertheless, these findings do demonstrate the importance of appropriate timing of drug administration to correspond with the endogenous clock and sleep/wake cycle, in order to ensure that patients’ are not sleeping at the wrong time of day and to prevent further sleep and circadian disturbance.

Influence of the Circadian Clock and Sleep on Dopamine Signaling

Studies detailed above demonstrate that DA is able to modulate the entrainment of the central circadian clock and its outputs, as well drive behavioral oscillators and modulate circadian clocks outside of the SCN. Interestingly the link between DA and the circadian clock is bidirectional, with DA also being under the control of the clock.

Several elements of DA signaling have a diurnal rhythm, including expression of DA receptors and tyrosine hydroxylase (TH), the rate-limiting enzyme in DA synthesis (Castañeda et al., 2004; Weber et al., 2004; Ferris et al., 2014; Ozburn et al., 2015; Sidor et al., 2015). Numerous rodent studies have reported diurnal changes in extracellular DA levels in various brain regions such as the prefrontal cortex and nucleus accumbens, with generally higher levels at night when rodents are active (Smith et al., 1992; Hood et al., 2010; Menon et al., 2019). Similarly, circulating DA levels in men peak during the day (Sowers and Vlachakis, 1984).

Evidence suggests that these diurnal rhythms are driven by direct regulation of DA signaling components by the circadian clock. The synthetic enzyme TH is under direct transcriptional control by both CLOCK (Sidor et al., 2015) and REV-ERBα (Chung et al., 2014); their genetic ablation leads to elevated DA signaling, with an increase in active TH and firing of dopaminergic VTA neurons (McClung et al., 2005; Chung et al., 2014). Furthermore NPAS2 directly regulates expression of the DA receptor gene Drd3, and is required for its rhythmic expression in the nucleus accumbens (Ozburn et al., 2015). In addition, the enzyme monoamine oxidase A (MAOA), which is required for DA metabolism, is also under circadian control; Per2 is required for its diurnal rhythm in expression, and Per2 mutant mice exhibit reduced MAOA activity and increased DA levels in the striatum (Hampp et al., 2008). Collectively, these studies demonstrate that DA signaling itself is rhythmic and is under direct circadian control.

There are also numerous lines of evidence that the DA system is modulated by melatonin. The MT1 melatonin receptors are expressed in dopaminergic regions of the rodent and human brain, including the VTA and nucleus accumbens where they exhibit diurnal changes in expression (Uz et al., 2005; Lacoste et al., 2015). Generally, studies have demonstrated an inhibitory effect of melatonin on the dopaminergic system, with an inhibition of DA release widely reported across species and brain regions (Zisapel and Laudon, 1982; Zisapel et al., 1982, 1985; Dubocovich, 1983; Boatright et al., 1994; Exposito et al., 1995), as well as an inhibition of dopaminergic neuronal firing (Domínguez-López et al., 2014). However at the molecular level, studies appear to indicate an enhancement of DA levels, with melatonin reported to increase TH activity (Alexiuk et al., 1996; McMillan et al., 2007), and decrease DA degradative enzyme activity (Esquifino et al., 1994; Stefanovic et al., 2016), as well as increase expression of vesicular monoamine transporter 2 (VMAT2; Stefanovic et al., 2016), which mediates synaptic release of DA. The mechanisms underlying the inhibitory action of melatonin are therefore unclear and its effects are likely to be dependent on both region and circadian time. Zisapel et al. (1985) demonstrated that melatonin inhibits dopamine in a time-dependent manner, suggesting that there is a circadian rhythm in its sensitivity to melatonin. Nevertheless, melatonin clearly influences DA signaling and therefore abnormalities in the melatonin rhythm, such as has been observed in schizophrenia, may disturb the DA system.

There are also changes in extracellular DA levels across the spontaneous sleep/wake cycle. The fluctuations vary between brain regions, but generally levels are higher during wakefulness (Léna et al., 2005; Dong et al., 2019; Menon et al., 2019). In the mouse striatum, DA levels also exhibit dynamic changes within periods of wakefulness and at sleep/wake state transitions (Dong et al., 2019). Given the potent wake-promoting activity of DA, it is currently unclear whether this correlation of DA levels with sleep/wake state is dependent on the sleep/wake cycle or whether elevated DA precedes wakefulness onset. However, there is evidence that sleep deprivation leads to an increase in DA in the nucleus accumbens (Murillo-Rodríguez et al., 2016), suggesting that sleep can modulate DA levels.

Bidirectional Relationship Between Dopamine and Sleep and Circadian Systems

Overall, it is clear that DA and the sleep and circadian systems interact at multiple levels, and this reciprocal relationship may be a key element of schizophrenia pathophysiology. Numerous studies outlined here have demonstrated the involvement of DA in the regulation of both sleep and circadian rhythms. It is therefore implicated that alterations to DA signaling, such that occur in schizophrenia, would lead to disruptions to sleep and circadian rhythms. Indeed, elevation of DA signaling through genetic and pharmacological approaches leads to disrupted sleep and fragmented rest/activity rhythms (Wisor et al., 2001; Monti and Monti, 2007; Blum et al., 2014). Furthermore, circadian rhythm disturbances and disrupted sleep/wake cycles are common in Parkinson’s disease, in which degeneration of nigrostriatal dopaminergic neurons leads to altered DA signaling (Videnovic et al., 2014; Grippo and Güler, 2019). Therefore dysregulation of the DA system can lead to disruption to sleep and circadian rhythms, and so this may be a key mechanism underlying the SCRD in schizophrenia.

On the other hand, DA is also under the control of the circadian clock and exhibits sleep-dependent changes, therefore it is likely that SCRD will lead to dysregulation of the DA system. SCRD is a key feature of schizophrenia pathophysiology, it largely occurs independent of medication status or disease stage (Karatsoreos, 2014) and there is compelling evidence for a causal role of SCRD in schizophrenia. Indeed, studies outlined above have demonstrated that an intact clock is required for normal levels of DA activity and rhythmic expression of DA signaling components, with alterations to clock gene expression causing elevations in dopaminergic tone. Furthermore, destabilization of the sleep/wake cycle can cause aberrant DA signaling, with sleep deprivation resulting in increased DA activity (Volkow et al., 2008; Zant et al., 2011; Murillo-Rodríguez et al., 2016).

Therefore, overall the DA system and the sleep and circadian systems are key modulators of each other. The two have a bidirectional relationship whereby dysregulation of one will lead to disturbances to the other, this will likely lead to a positive feedback loop in which the two exacerbate each other (Figure 3). Given that both aberrant DA signaling and SCRD are implicated in schizophrenia pathogenesis, this interplay may be an important process in the development of the disorder. Studies assessing the outcome of early intervention to address sleep and circadian disturbances in the prodromal stages will help to elucidate the causal role of this bidirectional relationship in schizophrenia.

FIGURE 3.

FIGURE 3

Open in a new tab

Schematic of the bidirectional relationship of dopamine signaling with sleep and circadian rhythm disruption (SCRD). The dopamine (DA) system is involved in sleep-wake control and circadian rhythms, therefore aberrant DA signaling will result in disruption to sleep and circadian rhythms. On the other hand, DA is also under the control of the circadian clock and its activity varies with sleep stage, therefore SCRD, arising from dysregulation of the DA system itself, or genetic or environmental factors, will aberrantly impact DA signaling. Dysregulation to each of these systems will exacerbate each other; disturbances to one will worsen abnormalities in the other, forming a positive feedback cycle. This process may be an important mechanism underlying schizophrenia pathogenesis and progression of the illness.

Conclusion

Sleep and circadian rhythm disruption is a key feature of schizophrenia, with deficits present from the level of the molecular clock up to behavioral rhythms. Studies discussed here demonstrate that DA signaling is an important modulator of sleep and circadian rhythms, and therefore constitutes a common mechanism underlying both sleep and circadian rhythm regulation, and schizophrenia pathophysiology. On the other hand, DA is also influenced by the circadian clock and sleep, and the close reciprocal relationship of the two systems appears to be important in the development of schizophrenia. Whilst further understanding of the mechanisms underlying this complex interaction is needed, there are already several potential pathways where dysregulation of DA can lead to disturbances to sleep and circadian rhythms, suggesting that aberrant DA may lead to SCRD in schizophrenia. Nevertheless, targeting sleep and the circadian system holds valuable therapeutic potential to improve symptoms and quality of life for patients.

Author Contributions

AA and AJ have both contributed to the writing of the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of Interest

AJ is in receipt of funding from Circadian Therapeutics Ltd. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to thank the research topic editors for the invitation to write this review.

Footnotes

Funding. Funding was provided by a BBSRC David Phillips Fellowship grant (BB/N01992X/1) awarded to AJ, which funds AA and AJ. AJ is also in receipt of funding from Circadian Therapeutics Ltd.

References

  1. Afonso P., Brissos S., Figueira M. L., Paiva T. (2011). Schizophrenia patients with predominantly positive symptoms have more disturbed sleep-wake cycles measured by actigraphy. Psychiatry Res. 189 62–66. 10.1016/j.psychres.2010.12.031 [DOI] [PubMed] [Google Scholar]
  2. Alexiuk N. A. M., Uddin M., Vriend J. (1996). Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male syrian hamsters. Life Sci. 59 687–694. 10.1016/0024-3205(96)00350-5 [DOI] [PubMed] [Google Scholar]
  3. Bastos M. A. V., Oliveira Bastos P. R. H., de Portella R. B., Soares L. F. G., Conde R. B., Rodrigues P. M. F., et al. (2019). Pineal gland and schizophrenia: a systematic review and meta-analysis. Psychoneuroendocrinology 104 100–114. 10.1016/j.psyneuen.2019.02.024 [DOI] [PubMed] [Google Scholar]
  4. Bertram R., Helena C., Gonzalez-Iglesias A. E., Tabak J., Freeman M. E. (2010). A tale of two rhythms: the emerging roles of oxytocin in rhythmic prolactin release. J. Neuroendocrinol. 22 778–784. 10.1111/j.1365-2826.2010.02012.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blum I. D., Zhu L., Moquin L., Kokoeva M. V., Gratton A., Giros B., et al. (2014). A highly tunable dopaminergic oscillator generates ultradian rhythms of behavioral arousal. eLife 3:105. 10.7554/eLife.05105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boatright J. H., Rubim N. M., Iuvone P. M. (1994). Regulation of endogenous dopamine release in amphibian retina by melatonin: the role of GABA. Vis. Neurosci. 11 1013–1018. 10.1017/S0952523800003941 [DOI] [PubMed] [Google Scholar]
  7. Borbely A. A., Achermann P. (1999). Sleep homeostasis and models of sleep regulation. J. Biol. Rhythms 14 559–570. 10.1177/074873099129000894 [DOI] [PubMed] [Google Scholar]
  8. Boutrel B., Koob G. F. (2004). What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 27 1181–1194. 10.1093/sleep/27.6.1181 [DOI] [PubMed] [Google Scholar]
  9. Bromundt V., Köster M., Georgiev-Kill A., Opwis K., Wirz-Justice A., Stoppe G., et al. (2011). Sleep - Wake cycles and cognitive functioning in schizophrenia. Br. J. Psychiatry 198 269–276. 10.1192/bjp.bp.110.078022 [DOI] [PubMed] [Google Scholar]
  10. Castañeda T. R., Marquez De Prado B., Prieto D., Mora F. (2004). Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 36 177–185. 10.1046/j.1600-079X.2003.00114.x [DOI] [PubMed] [Google Scholar]
  11. Castro J., Zanini M., Gonçalves B., da S. B., Coelho F. M. S., Bressan R., et al. (2015). Circadian rest-activity rhythm in individuals at risk for psychosis and bipolar disorder. Schizophr. Res. 168 50–55. 10.1016/j.schres.2015.07.024 [DOI] [PubMed] [Google Scholar]
  12. Cepeda C., Buchwald N. A., Levine M. S. (1993). Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. U.S.A. 90 9576–9580. 10.1073/pnas.90.20.9576 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cepeda C., Colwell C. S., Itri J. N., Chandler S. H., Levine M. S. (1998). Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J. Neurophysiol. 79 82–94. 10.1152/jn.1998.79.1.82 [DOI] [PubMed] [Google Scholar]
  14. Chai X. J., Whitfield-Gabrieli S., Shinn A. K., Gabrieli J. D. E., Nieto Castãón A., McCarthy J. M., et al. (2011). Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia. Neuropsychopharmacology 36 2009–2017. 10.1038/npp.2011.88 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chan M. S., Chung K. F., Yung K. P., Yeung W. F. (2017). Sleep in schizophrenia: a systematic review and meta-analysis of polysomnographic findings in case-control studies. Sleep Med. Rev. 32 69–84. 10.1016/j.smrv.2016.03.001 [DOI] [PubMed] [Google Scholar]
  16. Cho J. R., Treweek J. B., Robinson J. E., Xiao C., Bremner L. R., Greenbaum A., et al. (2017). Dorsal raphe dopamine neurons modulate arousal and promote wakefulness by salient stimuli. Neuron 94 1205–1219. 10.1016/J.NEURON.2017.05.020 [DOI] [PubMed] [Google Scholar]
  17. Chouinard S., Poulin J., Stip E., Godbout R. (2004). Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr. Bull. 30 957–967. 10.1093/oxfordjournals.schbul.a007145 [DOI] [PubMed] [Google Scholar]
  18. Chung S., Lee E. J., Yun S., Choe H. K., Park S. B., Son H. J., et al. (2014). Impact of circadian nuclear receptor REV-ERBα on midbrain dopamine production and mood regulation. Cell 157 858–868. 10.1016/j.cell.2014.03.039 [DOI] [PubMed] [Google Scholar]
  19. Ciruela F., Gómez-Soler M., Guidolin D., Borroto-Escuela D. O., Agnati L. F., Fuxe K., et al. (2011). Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim. Biophys. Acta Biomembr. 1808 1245–1255. 10.1016/J.BBAMEM.2011.02.007 [DOI] [PubMed] [Google Scholar]
  20. Cohrs S. (2008). Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 22 939–962. 10.2165/00023210-200822110-00004 [DOI] [PubMed] [Google Scholar]
  21. Coogan A. N., Papachatzaki M. M., Clemens C., Baird A., Donev R. M., Joosten J., et al. (2011). Haloperidol alters circadian clock gene product expression in the mouse brain. World J. Biol. Psychiatry 12 638–644. 10.3109/15622975.2010.543149 [DOI] [PubMed] [Google Scholar]
  22. Cosgrave J., Haines R., van Heugten-van der Kloet D., Purple R., Porcheret K., Foster R., et al. (2018a). The interaction between subclinical psychotic experiences, insomnia and objective measures of sleep. Schizophr. Res. 193 204–208. 10.1016/j.schres.2017.06.058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Cosgrave J., Wulff K., Gehrman P. (2018b). Sleep, circadian rhythms, and schizophrenia: where we are and where we need to go. Curr. Opin. Psychiatry 31 176–182. 10.1097/YCO.0000000000000419 [DOI] [PubMed] [Google Scholar]
  24. da Silva Araújo T., Maia Chaves, Filho A. J., Monte A. S., Isabelle, et al. (2017). Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. J. Psychiatr. Res. 84 49–58. 10.1016/j.jpsychires.2016.09.017 [DOI] [PubMed] [Google Scholar]
  25. Dahan L., Astier B., Vautrelle N., Urbain N., Kocsis B., Chouvet G. (2007). Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. Neuropsychopharmacology 32 1232–1241. 10.1038/sj.npp.1301251 [DOI] [PubMed] [Google Scholar]
  26. Dibner C., Schibler U., Albrecht U. (2010). The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 72 517–549. 10.1146/annurev-physiol-021909-135821 [DOI] [PubMed] [Google Scholar]
  27. Doi M., Yujnovsky I., Hirayama J., Malerba M., Tirotta E., Sassone-Corsi P., et al. (2006). Impaired light masking in dopamine D2 receptor-null mice. Nat. Neurosci. 9 732–734. 10.1038/nn1711 [DOI] [PubMed] [Google Scholar]
  28. Domínguez-López S., Howell R. D., López-Canúl M. G., Leyton M., Gobbi G. (2014). Electrophysiological characterization of dopamine neuronal activity in the ventral tegmental area across the light-dark cycle. Synapse 68 454–467. 10.1002/syn.21757 [DOI] [PubMed] [Google Scholar]
  29. Dong H., Wang J., Yang Y.-F., Shen Y., Qu W.-M., Huang Z.-L. (2019). Dorsal striatum dopamine levels fluctuate across the sleep-wake cycle and respond to salient stimuli in mice. Front. Neurosci. 13:242. 10.3389/fnins.2019.00242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Dubocovich M. L. (1983). Melatonin is a potent modulator of dopamine release in the retina. Nature 306 782–784. 10.1038/306782a0 [DOI] [PubMed] [Google Scholar]
  31. Duffield G. E., Hastings M. H., Ebling F. J. P. (1998). Investigation into the regulation of the circadian system by dopamine and melatonin in the adult siberian hamster (Phodopus sungorus). J. Neuroendocrinol. 10 871–884. 10.1046/j.1365-2826.1998.00274.x [DOI] [PubMed] [Google Scholar]
  32. Eban-Rothschild A., Appelbaum L., De Lecea L. (2018). Neuronal mechanisms for sleep/wake regulation and modulatory drive. Neuropsychopharmacology 43 937–952. 10.1038/npp.2017.294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Eban-Rothschild A., Rothschild G., Giardino W. J., Jones J. R., de Lecea L. (2016). VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors. Nat. Neurosci. 19 1356–1366. 10.1038/nn.4377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Esquifino A. I., Moreno M. L., Steger R. W. (1994). Effects of chronic melatonin administration on adrenal medulla catecholamine metabolism in adult male golden hamsters. J. Pineal Res. 16 154–158. 10.1111/j.1600-079X.1994.tb00095.x [DOI] [PubMed] [Google Scholar]
  35. Exposito I., Mora F., Zisapel N., Oaknin S. (1995). The modulatory effect of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus during ageing. Neuroreport 6 2399–2403. 10.1097/00001756-199511270-00029 [DOI] [PubMed] [Google Scholar]
  36. Ferré S., Fuxe K., Fredholm B., Morelli M., Popoli P. (1997). Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 482–487. 10.1016/S0166-2236(97)01096-5 [DOI] [PubMed] [Google Scholar]
  37. Ferris M. J., España R. A., Locke J. L., Konstantopoulos J. K., Rose J. H., Chen R., et al. (2014). Dopamine transporters govern diurnal variation in extracellular dopamine tone. Proc. Natl. Acad. Sci. U.S.A. 111 E2751–E2759. 10.1073/pnas.1407935111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Freeman D., Sheaves B., Goodwin G. M., Yu L. M., Nickless A., Harrison P. J., et al. (2017). The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis. Lancet Psychiatry 4 749–758. 10.1016/S2215-0366(17)30328-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Gallardo C. M., Darvas M., Oviatt M., Chang C. H., Michalik M., Huddy T. F., et al. (2014). Dopamine receptor 1 neurons in the dorsal striatum regulate food anticipatory circadian activity rhythms in mice. eLife 3:3781. 10.7554/eLife.03781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Golombek D. A., Rosenstein R. E. (2010). Physiology of Circadian Entrainment. Physiol. Rev. 90 1063–1102. 10.1152/physrev.00009.2009 [DOI] [PubMed] [Google Scholar]
  41. González S., Moreno-Delgado D., Moreno E., Pérez-Capote K., Franco R., Mallol J., et al. (2012). Circadian-related heteromerization of adrenergic and dopamine D4 receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biol. 10:e1001347. 10.1371/journal.pbio.1001347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Gould R. W., Nedelcovych M. T., Gong X., Tsai E., Bubser M., Bridges T. M., et al. (2016). State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - relation to antipsychotic-like drug effects. Neuropharmacology 102 244–253. 10.1016/j.neuropharm.2015.11.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Green C. B., Besharse J. C. (2004). Retinal circadian clocks and control of retinal physiology. J. Biol. Rhythms 19 91–102. 10.1177/0748730404263002 [DOI] [PubMed] [Google Scholar]
  44. Grippo R. M., Güler A. D. (2019). Dopamine signaling in circadian photoentrainment: consequences of desynchrony. Yale J. Biol. Med. 92 2 71–281. [PMC free article] [PubMed] [Google Scholar]
  45. Grippo R. M., Purohit A. M., Zhang Q., Zweifel L. S., Güler A. D. (2017). Direct midbrain dopamine input to the suprachiasmatic nucleus accelerates circadian entrainment. Curr. Biol. 27 2465–2475. 10.1016/j.cub.2017.06.084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Grosse J., Davis F. C. (1999). Transient entrainment of a circadian pacemaker during development by dopaminergic activation in Syrian hamsters. Brain Res. Bull. 48 185–194. 10.1016/S0361-9230(98)00162-2 [DOI] [PubMed] [Google Scholar]
  47. Hamidovic A., Kang U. J., de Wit H. (2008). Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J. Clin. Psychopharmacol. 28 45–51. 10.1097/jcp.0b013e3181602fab [DOI] [PubMed] [Google Scholar]
  48. Hampp G., Ripperger J. A., Houben T., Schmutz I., Blex C., Perreau-Lenz S., et al. (2008). Regulation of monoamine oxidase a by circadian-clock components implies clock influence on mood. Curr. Biol. 18 678–683. 10.1016/J.CUB.2008.04.012 [DOI] [PubMed] [Google Scholar]
  49. Hofstetter J. R., Lysaker P. H., Mayeda A. R. (2005). Quality of sleep in patients with schizophrenia is associated with quality of life and coping. BMC Psychiatry 5:13. 10.1186/1471-244X-5-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Hood S., Cassidy P., Cossette M.-P., Weigl Y., Verwey M., Robinson B., et al. (2010). Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J. Neurosci. 30 14046–14058. 10.1523/JNEUROSCI.2128-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Huang Z.-L., Qu W.-M., Eguchi N., Chen J.-F., Schwarzschild M. A., Fredholm B. B., et al. (2005). Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat. Neurosci. 8 858–859. 10.1038/nn1491 [DOI] [PubMed] [Google Scholar]
  52. Isobe Y., Nishino H. (2001). Circadian rhythm of drinking and running-wheel activity in rats with 6-hydroxydopamine lesions of the ventral tegmental area. Brain Res. 899 187–192. 10.1016/S0006-8993(01)02223-5 [DOI] [PubMed] [Google Scholar]
  53. Jackson C. R., Ruan G.-X., Aseem F., Abey J., Gamble K., Stanwood G., et al. (2012). Retinal dopamine mediates multiple dimensions of light-adapted vision. J. Neurosci. 32 9359–9368. 10.1523/JNEUROSCI.0711-12.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Jagannath A., Peirson S. N., Foster R. G. (2013). Sleep and circadian rhythm disruption in neuropsychiatric illness. Curr. Opin. Neurobiol. 23 888–894. 10.1016/j.conb.2013.03.008 [DOI] [PubMed] [Google Scholar]
  55. Johansson A. S., Owe-Larsson B., Hetta J., Lundkvist G. B. (2016). Altered circadian clock gene expression in patients with schizophrenia. Schizophr. Res. 174 17–23. 10.1016/j.schres.2016.04.029 [DOI] [PubMed] [Google Scholar]
  56. Jones J. R., Tackenberg M. C., McMahon D. G. (2015). Manipulating circadian clock neuron firing rate resets molecular circadian rhythms and behavior. Nat. Neurosci. 18 373–375. 10.1038/nn.3937 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Kajimura N., Kato M., Okuma T., Sekimoto M., Watanabe T., Takahashi K. (1995). A quantitative sleep-EEG study on the effects of benzodiazepine and zopiclone in schizophrenic patients. Schizophr. Res. 15 303–312. 10.1016/0920-9964(94)00054-C [DOI] [PubMed] [Google Scholar]
  58. Karatsoreos I. N. (2014). Links between circadian rhythms and psychiatric disease. Front. Behav. Neurosci. 8:162. 10.3389/fnbeh.2014.00162 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Klein M. O., Battagello D. S., Cardoso A. R., Hauser D. N., Bittencourt J. C., Correa R. G. (2019). Dopamine: functions, signaling, and association with neurological diseases. Cell. Mol. Neurobiol. 39 31–59. 10.1007/s10571-018-0632-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Kluge M., Schacht A., Himmerich H., Rummel-Kluge C., Wehmeier P. M., Dalal M., et al. (2014). Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature. Schizophr. Res. 152 255–260. 10.1016/J.SCHRES.2013.11.009 [DOI] [PubMed] [Google Scholar]
  61. Kumar P. N. S., Andrade C., Bhakta S. G., Singh N. M. (2007). Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J. Clin. Psychiatry 68 237–241. 10.4088/JCP.v68n0208 [DOI] [PubMed] [Google Scholar]
  62. Lacoste B., Angeloni D., Dominguez-Lopez S., Calderoni S., Mauro A., Fraschini F., et al. (2015). Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain. J. Pineal Res. 58 397–417. 10.1111/jpi.12224 [DOI] [PubMed] [Google Scholar]
  63. Laloux C., Derambure P., Houdayer E., Jacquesson J.-M., Bordet R., Destée A., et al. (2008). Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice. J. Sleep Res. 17 101–110. 10.1111/j.1365-2869.2008.00625.x [DOI] [PubMed] [Google Scholar]
  64. Landgraf D., Joiner W. J., McCarthy M. J., Kiessling S., Barandas R., Young J. W., et al. (2016). The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms. Neuropharmacology 107 262–270. 10.1016/J.NEUROPHARM.2016.03.047 [DOI] [PubMed] [Google Scholar]
  65. Landolt H.-P. (2008). Sleep homeostasis: a role for adenosine in humans? Biochem. Pharmacol. 75 2070–2079. 10.1016/J.BCP.2008.02.024 [DOI] [PubMed] [Google Scholar]
  66. Léna I., Parrot S., Deschaux O., Muffat-Joly S., Sauvinet V., Renaud B., et al. (2005). Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J. Neurosci. Res. 81 891–899. 10.1002/jnr.20602 [DOI] [PubMed] [Google Scholar]
  67. Levine M. S., Altemus K. L., Cepeda C., Cromwell H. C., Crawford C., Ariano M. A., et al. (1996). Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. J. Neurosci. 16 5870–5882. 10.1523/JNEUROSCI.16-18-05870.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Liu Y.-Y., Liu T.-Y., Qu W.-M., Hong Z.-Y., Urade Y., Huang Z.-L. (2012). Dopamine is involved in food-anticipatory activity in mice. J. Biol. Rhythms 27 398–409. 10.1177/0748730412455913 [DOI] [PubMed] [Google Scholar]
  69. Lu J., Jhou T. C., Saper C. B. (2006). Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J. Neurosci. 26 193–202. 10.1523/JNEUROSCI.2244-05.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Luca G., Bandarabadi M., Konofal E., Lecendreux M., Ferrié L., Figadère B., et al. (2018). Lauflumide (NLS-4) is a new potent wake-promoting compound. Front. Neurosci. 12:519. 10.3389/fnins.2018.00519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Lunsford-Avery J. R., Gonçalves B., da S. B., Brietzke E., Bressan R. A., Gadelha A., et al. (2017). Adolescents at clinical-high risk for psychosis: circadian rhythm disturbances predict worsened prognosis at 1-year follow-up. Schizophr. Res. 189 37–42. 10.1016/j.schres.2017.01.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Manoach D. S., Pan J. Q., Purcell S. M., Stickgold R. (2016). Reduced sleep spindles in schizophrenia: a treatable endophenotype that links risk genes to impaired cognition? Biol. Psychiatry 80 599–608. 10.1016/j.biopsych.2015.10.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Mansour H. A., Talkowski M. E., Wood J., Chowdari K. V., McClain L., Prasad K., et al. (2009). Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord. 11 701–710. 10.1111/j.1399-5618.2009.00756.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. McClung C. A., Sidiropoulou K., Vitaterna M., Takahashi J. S., White F. J., Cooper D. C., et al. (2005). Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc. Natl. Acad. Sci. U.S.A. 102 9377–9381. 10.1073/pnas.0503584102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. McMillan C. R., Sharma R., Ottenhof T., Niles L. P. (2007). Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci. Lett. 419 202–206. 10.1016/j.neulet.2007.04.029 [DOI] [PubMed] [Google Scholar]
  76. Mendoza J., Challet E. (2014). Circadian insights into dopamine mechanisms. Neuroscience 282 230–242. 10.1016/J.NEUROSCIENCE.2014.07.081 [DOI] [PubMed] [Google Scholar]
  77. Menon J. M. L., Nolten C., Marijke Achterberg E. J., Joosten R. N. J. M. A., Dematteis M., Feenstra M. G. P., et al. (2019). Brain microdialysate monoamines in relation to circadian rhythms, sleep, and sleep deprivation - A systematic review, network meta-analysis, and new primary data. J. Circ. Rhythms 17 1–32. 10.5334/jcr.174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Mishra A., Maiti R., Mishra B. R., Jena M., Nath S., Sahu P. (2020). Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: a randomized controlled trial. Eur. Neuropsychopharmacol. 31 109–118. 10.1016/j.euroneuro.2019.11.008 [DOI] [PubMed] [Google Scholar]
  79. Miyamoto S., Duncan G. E., Marx C. E., Lieberman J. A. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 79–104. 10.1038/sj.mp.4001556 [DOI] [PubMed] [Google Scholar]
  80. Modabbernia A., Heidari P., Soleimani R., Sobhani A., Roshan Z. A., Taslimi S., et al. (2014). Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J. Psychiatr. Res. 53 133–140. 10.1016/j.jpsychires.2014.02.013 [DOI] [PubMed] [Google Scholar]
  81. Monti J. M., Jantos H., Fernández M. (1989). Effects of the selective dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat. Eur. J. Pharmacol. 169 61–66. 10.1016/0014-2999(89)90817-0 [DOI] [PubMed] [Google Scholar]
  82. Monti J. M., Monti D. (2007). The involvement of dopamine in the modulation of sleep and waking. Sleep Med. Rev. 11 113–133. 10.1016/j.smrv.2006.08.003 [DOI] [PubMed] [Google Scholar]
  83. Moreno-Küstner B., Martín C., Pastor L. (2018). Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 13:e0195687. 10.1371/journal.pone.0195687 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Murillo-Rodríguez E., Machado S., Rocha N. B., Budde H., Yuan T. F., Arias-Carrión O. (2016). Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis. Neuroscience 339 433–449. 10.1016/j.neuroscience.2016.10.011 [DOI] [PubMed] [Google Scholar]
  85. Murphy J. A., Stein I. S., Lau C. G., Peixoto R. T., Aman T. K., Kaneko N., et al. (2014). Phosphorylation of Ser1166 on GluN2B by PKA is critical to synaptic NMDA receptor function and Ca2+ signaling in spines. J. Neurosci. 34 869–879. 10.1523/JNEUROSCI.4538-13.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Myers E., Startup H., Freeman D. (2011). Cognitive behavioural treatment of insomnia in individuals with persistent persecutory delusions: a pilot trial. J. Behav. Ther. Exp. Psychiatry. 42 330–336. 10.1016/j.jbtep.2011.02.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Ng T. H., Chung K.-F., Ho F. Y.-Y., Yeung W.-F., Yung K.-P., Lam T.-H. (2015). Sleep-wake disturbance in interepisode bipolar disorder and high-risk individuals: a systematic review and meta-analysis. Sleep Med. Rev. 20, 46–58. 10.1016/j.smrv.2014.06.006 [DOI] [PubMed] [Google Scholar]
  88. Nishino S., Mao J., Sampathkumaran R., Shelton J. (1998). Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. 1 49–61. [PubMed] [Google Scholar]
  89. Oishi Y., Suzuki Y., Takahashi K., Yonezawa T., Kanda T., Takata Y., et al. (2017). Activation of ventral tegmental area dopamine neurons produces wakefulness through dopamine D2-like receptors in mice. Brain Struct. Funct. 222 2907–2915. 10.1007/s00429-017-1365-7 [DOI] [PubMed] [Google Scholar]
  90. Oliver P. L., Sobczyk M. V., Maywood E. S., Edwards B., Lee S., Livieratos A., et al. (2012). Disrupted circadian rhythms in a mouse model of schizophrenia. Curr. Biol. 22 314–319. 10.1016/j.cub.2011.12.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Onaolapo A. Y., Aina O. A., Onaolapo O. J. (2017). Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia. Biomed. Pharmacother. 92 373–383. 10.1016/j.biopha.2017.05.094 [DOI] [PubMed] [Google Scholar]
  92. Ongini E., Bonizzoni E., Ferri N., Milani S., Trampus M. (1993). Differential effects of dopamine D-1 and D-2 receptor antagonist antipsychotics on sleep-wake patterns in the rat. J. Pharmacol. Exp. Ther. 266 726–731. [PubMed] [Google Scholar]
  93. Ozburn A. R., Falcon E., Twaddle A., Nugent A. L., Gillman A. G., Spencer S. M., et al. (2015). Direct regulation of diurnal drd3 expression and cocaine reward by NPAS2. Biol. Psychiatry 77 425–433. 10.1016/J.BIOPSYCH.2014.07.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Palmese L. B., DeGeorge P. C., Ratliff J. C., Srihari V. H., Wexler B. E., Krystal A. D., et al. (2011). Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophr. Res. 133 238–243. 10.1016/j.schres.2011.07.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Pardiñas A. F., Holmans P., Pocklington A. J., Escott-Price V., Ripke S., Carrera N., et al. (2018). Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50 381–389. 10.1038/s41588-018-0059-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Park H. J., Park J. K., Kim S. K., Cho A. R., Kim J. W., Yim S. V., et al. (2011). Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J. Mol. Neurosci. 45 304–308. 10.1007/s12031-011-9522-6 [DOI] [PubMed] [Google Scholar]
  97. Pascoli V., Besnard A., Hervé D., Pagès C., Heck N., Girault J.-A., et al. (2011). Cyclic adenosine monophosphate-independent tyrosine phosphorylation of NR2B mediates cocaine-induced extracellular signal-regulated kinase activation. Biol. Psychiatry 69 218–227. 10.1016/J.BIOPSYCH.2010.08.031 [DOI] [PubMed] [Google Scholar]
  98. Peirson S., Foster R. G. (2006). Melanopsin: another way of signaling light. Neuron 49, 331–339. 10.1016/J.NEURON.2006.01.006 [DOI] [PubMed] [Google Scholar]
  99. Perreault M. L., Hasbi A., O’dowd B. F., George S. R. (2014). Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology 39 156–168. 10.1038/npp.2013.148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Petrovsky N., Ettinger U., Hill A., Frenzel L., Meyho I., Wagner M., et al. (2014). Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. J. Neurosci. 34 9134–9140. 10.1523/JNEUROSCI.0904-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Pompili M., Lester D., Grispini A., Innamorati M., Calandro F., Iliceto P., et al. (2009). Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res. 167 251–257. 10.1016/j.psychres.2008.03.018 [DOI] [PubMed] [Google Scholar]
  102. Qiu M.-H., Yao Q.-L., Vetrivelan R., Chen M. C., Lu J. (2016). Nigrostriatal dopamine acting on globus pallidus regulates sleep. Cereb. Cortex 26 1430–1439. 10.1093/cercor/bhu241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Qu W.-M., Huang Z.-L., Xu X.-H., Matsumoto N., Urade Y. (2008). Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J. Neurosci. 28 8462–8469. 10.1523/JNEUROSCI.1819-08.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Rees E., Carrera N., Morgan J., Hambridge K., Escott-Price V., Pocklington A. J., et al. (2019). Targeted sequencing of 10,198 samples confirms abnormalities in neuronal activity and implicates voltage-gated sodium channels in schizophrenia pathogenesis. Biol. Psychiatry 85 554–562. 10.1016/j.biopsych.2018.08.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Reeve S., Emsley R., Sheaves B., Freeman D. (2018). Disrupting sleep: the effects of sleep loss on psychotic experiences tested in an experimental study with mediation analysis. Schizophr. Bull. 44 662–671. 10.1093/schbul/sbx103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Reppert S. M., Weaver D. R. (2002). Coordination of circadian timing in mammals. Nature 418 935–941. 10.1038/nature00965 [DOI] [PubMed] [Google Scholar]
  107. Romo-Nava F., Alvarez-Icaza González D., Fresán-Orellana A., Saracco Alvarez R., Becerra-Palars C., Moreno J., et al. (2014). Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 16 410–421. 10.1111/bdi.12196 [DOI] [PubMed] [Google Scholar]
  108. Ryczko D., Dubuc R. (2017). Dopamine and the brainstem locomotor networks: from lamprey to human. Front. Neurosci. 11:295. 10.3389/fnins.2017.00295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Sakamoto K., Liu C., Kasamatsu M., Pozdeyev N. V., Iuvone P. M., Tosini G. (2005). Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. Eur. J. Neurosci. 22 3129–3136. 10.1111/j.1460-9568.2005.04512.x [DOI] [PubMed] [Google Scholar]
  110. Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 421–427. 10.1038/nature13595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Seney M. L., Cahill K., Enwright J. F., Logan R. W., Huo Z., Zong W., et al. (2019). Diurnal rhythms in gene expression in the prefrontal cortex in schizophrenia. Nat. Commun. 10:3355. 10.1038/s41467-019-11335-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Shamir E., Laudon M., Barak Y., Anis Y., Rotenberg V., Elizur A., et al. (2000). Melatonin improves sleep quality of patients with chronic schizophrenia. J. Clin. Psychiatry 61 373–377. 10.4088/JCP.v61n0509 [DOI] [PubMed] [Google Scholar]
  113. Sidor M. M., Spencer S. M., Dzirasa K., Parekh P. K., Tye K. M., Warden M. R., et al. (2015). Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol. Psychiatry 20 1406–1419. 10.1038/mp.2014.167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Smith A. D., Olson R. J., Justice J. B. (1992). Quantitative microdialysis of dopamine in the striatum: effect of circadian variation. J. Neurosci. Methods 44 33–41. 10.1016/0165-0270(92)90111-P [DOI] [PubMed] [Google Scholar]
  115. Smyllie N. J., Chesham J. E., Hamnett R., Maywood E. S., Hastings M. H. (2016). Temporally chimeric mice reveal flexibility of circadian period-setting in the suprachiasmatic nucleus. Proc. Natl. Acad. Sci. U.S.A. 113 3657–3662. 10.1073/pnas.1511351113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Sowers J. R., Vlachakis N. (1984). Circadian variation in plasma dopamine levels in man. J. Endocrinol. Invest. 7 341–345. 10.1007/BF03351014 [DOI] [PubMed] [Google Scholar]
  117. Spengler M. L., Kuropatwinski K. K., Comas M., Gasparian A. V., Fedtsova N., Gleiberman A. S., et al. (2012). Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription. Proc. Natl. Acad. Sci. U.S.A. 109 E2457–E2465. 10.1073/pnas.1206274109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Stefanovic B., Spasojevic N., Jovanovic P., Jasnic N., Djordjevic J., Dronjak S. (2016). Melatonin mediated antidepressant-like effect in the hippocampus of chronic stress-induced depression rats: regulating vesicular monoamine transporter 2 and monoamine oxidase A levels. Eur. Neuropsychopharmacol. 26 1629–1637. 10.1016/j.euroneuro.2016.07.005 [DOI] [PubMed] [Google Scholar]
  119. Sun H. Q., Li S. X., Chen F., Zhang Y., Li P., Jin M., et al. (2016). Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients. Psychoneuroendocrinology 64 108–116. 10.1016/j.psyneuen.2015.11.013 [DOI] [PubMed] [Google Scholar]
  120. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B. B., et al. (2000). Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. U.S.A. 97 1856–1860. 10.1073/pnas.97.4.1856 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Takao T., Tachikawa H., Kawanishi Y., Mizukami K., Asada T. (2007). CLOCK gene T3111C polymorphism is associated with Japanese schizophrenics: a preliminary study. Eur. Neuropsychopharmacol. 17 273–276. 10.1016/J.EURONEURO.2006.09.002 [DOI] [PubMed] [Google Scholar]
  122. Tanaka M., Yamaguchi E., Takahashi M., Hashimura K., Shibata T., Nakamura W., et al. (2012). Effects of age-related dopaminergic neuron loss in the substantia nigra on the circadian rhythms of locomotor activity in mice. Neurosci. Res. 74 210–215. 10.1016/J.NEURES.2012.09.005 [DOI] [PubMed] [Google Scholar]
  123. Tataroglu Ö, Davidson A. J., Benvenuto L. J., Menaker M. (2006). The methamphetamine-sensitive circadian oscillator (MASCO) in mice. J. Biol. Rhythms 21 185–194. 10.1177/0748730406287529 [DOI] [PubMed] [Google Scholar]
  124. Taylor N. E., Van Dort C. J., Kenny J. D., Pei J., Guidera J. A., Vlasov K. Y., et al. (2016). Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia. Proc. Natl. Acad. Sci. U.S.A. 113 12826–12831. 10.1073/pnas.1614340113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Uz T., Arslan A. D., Kurtuncu M., Imbesi M., Akhisaroglu M., Dwivedi Y., et al. (2005). The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Mol. Brain Res. 136 45–53. 10.1016/j.molbrainres.2005.01.002 [DOI] [PubMed] [Google Scholar]
  126. Videnovic A., Noble C., Reid K. J., Peng J., Turek F. W., Marconi A., et al. (2014). Circadian melatonin rhythm and excessive daytime sleepiness in parkinson disease. JAMA Neurol. 71 463. 10.1001/jamaneurol.2013.6239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Viyoch J., Matsunaga N., Yoshida M., To H., Higuchi S., Ohdo S. (2005). Effect of haloperidol on mPer1 gene expression in mouse suprachiasmatic nuclei. J. Biol. Chem. 280 6309–6315. 10.1074/jbc.M411704200 [DOI] [PubMed] [Google Scholar]
  128. Volk D. W., Moroco A. E., Roman K. M., Edelson J. R., Lewis D. A. (2019). The role of the nuclear factor-κB transcriptional complex in cortical immune activation in schizophrenia. Biol. Psychiatry 85 25–34. 10.1016/j.biopsych.2018.06.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Volkow N. D., Wang G.-J., Telang F., Fowler J. S., Logan J., Wong C., et al. (2008). Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain. J. Neurosci. 28 8454–8461. 10.1523/JNEUROSCI.1443-08.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Vos T., Abajobir A. A., Abate K. H., Abbafati C., Abbas K. M., Abd-Allah F., et al. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390 1211–1259. 10.1016/S0140-6736(17)32154-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Waite F., Myers E., Harvey A. G., Espie C. A., Startup H., Sheaves B., et al. (2016). Treating sleep problems in patients with schizophrenia. Behav. Cogn. Psychother. 44 273–287. 10.1017/S1352465815000430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Wang Q., Chen R., Cheng F., Wei Q., Ji Y., Yang H., et al. (2019). A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. Nat. Neurosci. 22 691–699. 10.1038/s41593-019-0382-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Waters F., Faulkner D., Naik N., Rock D. (2012). Effects of polypharmacy on sleep in psychiatric inpatients. Schizophr. Res. 139 225–228. 10.1016/j.schres.2012.05.013 [DOI] [PubMed] [Google Scholar]
  134. Weber M., Lauterburg T., Tobler I., Burgunder J.-M. (2004). Circadian patterns of neurotransmitter related gene expression in motor regions of the rat brain. Neurosci. Lett. 358 17–20. 10.1016/J.NEULET.2003.12.053 [DOI] [PubMed] [Google Scholar]
  135. Wirz-Justice A., Cajochen C., Nussbaum P. (1997). A schizophrenic patient with an arrhythmic circadian rest-activity cycle. Psychiatry Res. 73 83–90. 10.1016/S0165-1781(97)00117-0 [DOI] [PubMed] [Google Scholar]
  136. Wirz-Justice A., Haug H.-J., Cajochen C. (2001). Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs? Schizophr. Bull. 27 497–502. 10.1093/oxfordjournals.schbul.a006890 [DOI] [PubMed] [Google Scholar]
  137. Wisor J. P., Nishino S., Sora I., Uhl G. H., Mignot E., Edgar D. M. (2001). Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21 1787–1794. 10.1523/JNEUROSCI.21-05-01787.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Wulff K., Dijk D. J., Middleton B., Foster R. G., Joyce E. M. (2012). Sleep and circadian rhythm disruption in schizophrenia. Br. J. Psychiatry 200 308–316. 10.1192/bjp.bp.111.096321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Wulff K., Gatti S., Wettstein J. G., Foster R. G. (2010). Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat. Rev. Neurosci. 11 589–599. 10.1038/nrn2868 [DOI] [PubMed] [Google Scholar]
  140. Yamashita H., Mori K., Nagao M., Okamoto Y., Morinobu S., Yamawaki S. (2004). Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J. Clin. Psychiatry 65 1525–1530. 10.4088/JCP.v65n1114 [DOI] [PubMed] [Google Scholar]
  141. Yang S.-R., Hu Z.-Z., Luo Y.-J., Zhao Y.-N., Sun H.-X., Yin D., et al. (2018). The rostromedial tegmental nucleus is essential for non-rapid eye movement sleep. PLoS Biol. 16:e2002909. 10.1371/journal.pbio.2002909 [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Yujnovsky I., Hirayama J., Doi M., Borrelli E., Sassone-Corsi P. (2006). Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc. Natl. Acad. Sci. U.S.A. 103 6386–6391. 10.1073/pnas.0510691103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Zant J. C., Leenaars C. H. C., Kostin A., Van Someren E. J. W., Porkka-Heiskanen T. (2011). Increases in extracellular serotonin and dopamine metabolite levels in the basal forebrain during sleep deprivation. Brain Res. 1399 40–48. 10.1016/J.BRAINRES.2011.05.008 [DOI] [PubMed] [Google Scholar]
  144. Zhang J., Liao G., Liu C., Sun L., Liu Y., Wang Y., et al. (2011). The association of CLOCK gene T3111C polymorphism and hPER3 gene 54-nucleotide repeat polymorphism with Chinese han people schizophrenics. Mol. Biol. Rep. 38 349–354. 10.1007/s11033-010-0114-2 [DOI] [PubMed] [Google Scholar]
  145. Zisapel N., Egozi Y., Laudon M. (1982). Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res. 246 161–163. 10.1016/0006-8993(82)90157-3 [DOI] [PubMed] [Google Scholar]
  146. Zisapel N., Egozi Y., Laudon M. (1985). Circadian variations in the inhibition of dopamine release from adult and newborn rat hypothalamus by melatonin. Neuroendocrinology 40 102–108. 10.1159/000124062 [DOI] [PubMed] [Google Scholar]
  147. Zisapel N., Laudon M. (1982). Dopamine release induced by electrical field stimulation of rat hypothalamus invitro: inhibition by melatonin. Biochem. Biophys. Res. Commun. 104 1610–1616. 10.1016/0006-291X(82)91437-1 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES